NASDAQ:PPCB Propanc Biopharma (PPCB) Stock Price, News & Analysis $1.86 +0.02 (+0.82%) Closing price 11/12/2026 03:54 PM EasternExtended Trading$1.94 +0.08 (+4.31%) As of 11/12/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Propanc Biopharma Stock (NASDAQ:PPCB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Propanc Biopharma alerts:Sign Up Key Stats Today's Range$1.78▼$1.9950-Day Range$1.64▼$10.3052-Week Range$1.63▼$315.00Volume21,769 shsAverage Volume39,323 shsMarket Capitalization$1.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Propanc Biopharma, Inc. (NASDAQ:PPCB) is a clinical-stage biotechnology company focused on developing novel treatments for solid tumors, including pancreatic, ovarian and colorectal cancers. The company’s research is based on proenzyme therapy, an approach intended to selectively target cancer cells and cancer stem cells while limiting tumor growth, recurrence and metastasis. Propanc’s lead investigational product is PRP, also referred to as PRP-100, an intravenous formulation comprising the naturally occurring digestive proenzymes trypsinogen and chymotrypsinogen. The therapy is designed to become activated in the tumor environment and disrupt biological processes associated with cancer progression. PRP has been evaluated in early-stage clinical development for patients with advanced solid tumors. Propanc was established in Australia and has conducted its development activities there, including preclinical research and clinical work. The company’s programs remain focused on advancing its proenzyme-based platform toward potential treatments for difficult-to-treat cancers.AI Generated. May Contain Errors. Read More Propanc Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScorePPCB MarketRank™: 1.155706628315 of 5 starsPropanc Biopharma scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingPropanc Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoveragePropanc Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Propanc Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPropanc Biopharma has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.66% of the float of Propanc Biopharma has been sold short.Short Interest Ratio / Days to CoverPropanc Biopharma has a short interest ratio ("days to cover") of 0.34, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Propanc Biopharma has recently decreased by 60.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPropanc Biopharma does not currently pay a dividend.Dividend GrowthPropanc Biopharma does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.93 News SentimentPropanc Biopharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Propanc Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for PPCB on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Propanc Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders33.07% of the stock of Propanc Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsPropanc Biopharma has minimal institutional ownership at this time.Read more about Propanc Biopharma's insider trading history. Receive PPCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PPCB Stock News HeadlinesPropanc Biopharma (PPCB) AI Stock AnalysisNovember 6, 2026 | tipranks.comPropanc Biopharma Advances Bioanalytical Development For PPC-001 Solid Tumours TrialNovember 2, 2026 | rttnews.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found. | Crypto 101 Media (Ad)Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic CancerNovember 2, 2026 | globenewswire.comPropanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer PatientsOctober 30, 2026 | globenewswire.comPropanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer PatientsOctober 28, 2026 | globenewswire.comPropanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic VulnerabilityOctober 26, 2026 | globenewswire.comPropanc Biopharma Sets 1-for-10 Reverse Stock Split For October 26; Stock DownOctober 22, 2026 | rttnews.comSee More Headlines PPCB Stock Analysis - Frequently Asked Questions How have PPCB shares performed this year? Propanc Biopharma's stock was trading at $134.15 at the beginning of 2026. Since then, PPCB stock has decreased by 98.6% and is now trading at $1.8550. How were Propanc Biopharma's earnings last quarter? Propanc Biopharma Inc (NASDAQ:PPCB) posted its quarterly earnings results on Friday, September, 25th. The company reported ($17.74) earnings per share (EPS) for the quarter. When did Propanc Biopharma's stock split? Shares of Propanc Biopharma reverse split before market open on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How will Propanc Biopharma's stock buyback program work? Propanc Biopharma's Board of Directors authorized a share buyback program on Thursday, July 2nd 2026, which allows the company to repurchase $500 thousand in shares, according to EventVestor. This means that the company could buy up to 15.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's leadership believes its shares are undervalued. When did Propanc Biopharma IPO? Propanc Biopharma (PPCB) raised $5 million in an IPO on Friday, August 15th 2025. The company issued 1,000,000 shares at $4.00-$6.00 per share. D. Boral Capital (ex-EF Hutton) and Craft Capital served as the underwriters for the IPO. How do I buy shares of Propanc Biopharma? Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Propanc Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include Corbus Pharmaceuticals (CRBP), Delcath Systems (DCTH), Sirius XM (SIRI), C3.ai (AI), Petroteq Energy (PQEFF), Aurora Cannabis (ACBFF) and Aditxt (ADTX). Company Calendar Last Earnings9/25/2026Today11/12/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PPCB Previous SymbolOTCMKTS:PPCB CIK1517681 Webwww.propanc.com Phone(139) 882-0780Fax61 03 9882 9969Employees2Year Founded2007Profitability EPS (Trailing Twelve Months)($242.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-171.31% Return on Assets-125.33% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$28.40 per share Price / Book0.07Miscellaneous Outstanding Shares630,000Free Float424,000Market Cap$1.17 million OptionableNot Optionable Beta3.55 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:PPCB) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Propanc Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Propanc Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
